CANCER:

Endocrine Cancer

News alerts, weekly reports and conference planners

No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1	mitotane Sensitive: A1 - Approval mitotane Sensitive : A1
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2	cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive: A2 - Guideline cisplatin + carboplatin + etoposide IV + mitotane + SGN-15 Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2	cisplatin + etoposide IV Sensitive: A2 - Guideline cisplatin + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2	carboplatin + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2	carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2	carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive: A2 - Guideline carboplatin + doxorubicin hydrochloride + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2	cisplatin + etoposide IV + mitotane Sensitive: A2 - Guideline cisplatin + etoposide IV + mitotane Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2	cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + etoposide IV Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2	streptozocin Sensitive: A2 - Guideline streptozocin Sensitive : A2
No biomarker	Adrenal Cortex Carcinoma	No biomarker	Adrenal Cortex Carcinoma	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2	mitotane + streptozocin Sensitive: A2 - Guideline mitotane + streptozocin Sensitive : A2
MSI-H/dMMR	Adrenal Cortex Carcinoma	MSI-H/dMMR	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1	pembrolizumab Sensitive: C1 - Off-label pembrolizumab Sensitive : C1
RRM1 underexpression	Adrenal Cortex Carcinoma	RRM1 underexpression	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
TMB-L	Adrenal Cortex Carcinoma	TMB-L	Adrenal Cortex Carcinoma	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3	mitotane Sensitive: C3 – Early Trials mitotane Sensitive : C3
MGMT underexpression	Pituitary Gland Carcinoma	MGMT underexpression	Pituitary Gland Carcinoma	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma	TMB-L + PD-L1 underexpression	Pituitary Gland Carcinoma	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH2 mutation	Adrenal Cortex Carcinoma	MSH2 mutation	Adrenal Cortex Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
SDHB mutation	Pituitary Gland Carcinoma	SDHB mutation	Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4
MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4	temozolomide + capecitabine Resistant: C4 – Case Studies temozolomide + capecitabine Resistant : C4
STK11 mutation	Pituitary Gland Carcinoma	STK11 mutation	Pituitary Gland Carcinoma	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4	everolimus Sensitive: C4 – Case Studies everolimus Sensitive : C4
ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma	ATRX mutation + TP53 mutation + PTEN mutation	Pituitary Gland Carcinoma	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4	temozolomide Sensitive: C4 – Case Studies temozolomide Sensitive : C4
TMB-H	Pituitary Gland Carcinoma	TMB-H	Pituitary Gland Carcinoma	nivolumab + ipilimumab Resistant: C4 – Case Studies nivolumab + ipilimumab Resistant : C4	nivolumab + ipilimumab Resistant: C4 – Case Studies nivolumab + ipilimumab Resistant : C4
TMB-H	Pituitary Gland Carcinoma	TMB-H	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4
MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4
FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	FGFR3-TACC3 fusion	Adrenal Cortex Carcinoma	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4	erdafitinib Sensitive: C4 – Case Studies erdafitinib Sensitive : C4
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D	rubitecan Sensitive: D – Preclinical rubitecan Sensitive : D
TOP2A overexpression	Adrenal Cortex Carcinoma	TOP2A overexpression	Adrenal Cortex Carcinoma	teniposide Sensitive: D – Preclinical teniposide Sensitive : D	teniposide Sensitive: D – Preclinical teniposide Sensitive : D
CDK1 overexpression	Adrenal Cortex Carcinoma	CDK1 overexpression	Adrenal Cortex Carcinoma	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D	DSP-2033 Sensitive: D – Preclinical DSP-2033 Sensitive : D

Endocrine Cancer

Associations(50)

Associations
(50)